Pyxis Oncology Company
Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novel antibody-based immunotherapies. It was founded in 2019 and is based in Boston, Massachusetts.
Headquarters:
Boston, Massachusetts, United States
Last Funding Type:
Series B
Investors Number:
21
Last Funding Date:
2021
Employee Number:
11-50
Total Funding:
174000000
Founded Date:
2019-01-01
Investor Type:
Early Stage Venture
Industry:
Gene therapy
Funding Status:
IPO